Iovance Biotherapeutics Names Corleen Roche as CFO During Commercial Launch of First FDA-Approved TIL Therapy
Key Insights
Iovance Biotherapeutics appointed Corleen Roche as Chief Financial Officer effective August 6, 2025, during the commercial launch of its groundbreaking TIL therapy.
Roche brings 30 years of biotech experience including CFO roles at CG Oncology, Immunome, and Biogen, with expertise in multiple product launches.
The appointment comes as Iovance commercializes Amtagvi, the first FDA-approved T cell therapy for solid tumors, marking a significant milestone in cancer treatment.
Iovance Biotherapeutics has appointed Corleen Roche as Chief Financial Officer, effective August 6, 2025, as the company navigates the commercial launch of its groundbreaking tumor infiltrating lymphocyte (TIL) therapy platform. The appointment comes at a critical juncture for the San Carlos-based biotechnology company, which is commercializing Amtagvi, the first FDA-approved T cell therapy for a solid tumor indication.
"I am pleased to welcome Corleen to Iovance at such an important stage in our first commercial launch," said Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer, President and General Counsel. "Corleen's experience in executive financial leadership roles and multiple product launches will be invaluable as we focus on growing revenue, managing our balance sheet and advancing our mission of developing and delivering novel therapies to patients with solid tumors."
Extensive Industry Experience
Roche brings three decades of experience in the biotech and life sciences industry, including executive financial leadership roles in publicly traded companies. Most recently, she served as CFO of CG Oncology, a late-stage clinical biopharmaceutical company. Her previous roles included CFO of Immunome, U.S. CFO at Biogen, North America CFO of CSL Behring, and various CFO roles within Sandoz, Wyeth and Pfizer.
During her career, Roche developed and executed financial strategies to prepare for commercial launches of several significant products, including ZARXIO, the first U.S. approved biosimilar, GLATOPA, the world's first complex generic for multiple sclerosis, and PREVNAR 13, a pneumococcal conjugate vaccine. She holds a B.A. in accountancy from Villanova University.
Strategic Focus on Revenue Growth
"I am excited to join Iovance to navigate our continued revenue growth and focus our pipeline investments on the highest value opportunities," stated Roche. "I am committed to the company's patient-focused mission while achieving our financial goals to build a profitable biotechnology company."
The appointment positions Iovance to capitalize on its pioneering position in TIL therapy, with the company aiming to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte therapies for patients with cancer. The company is pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient.
Expanding TIL Platform
The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Beyond Amtagvi, the company has obtained FDA and European Medicines Agency approval for Proleukin. The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.
Iovance faces several operational challenges as it scales its commercial operations, including manufacturing capacity expansion, market acceptance of its products, and potential pricing and reimbursement considerations. The company has noted risks related to its ability to manufacture therapies using third-party manufacturers and at its own facility, which may adversely affect its commercial launch.
The company is also advancing clinical trials across multiple indications, including ongoing studies in non-small cell lung cancer and cervical cancer, with the planned single arm Phase 2 IOV-LUN-202 trial representing a key milestone in expanding the TIL platform's therapeutic reach.